Literature DB >> 22416356

[Semen-derived enhancer of viral infection--a key factor in sexual transmission of HIV].

Jiang-Man Duan1, Jia-Yin Qiu, Sui-Yi Tan, Shu-Wen Liu, Lin Li.   

Abstract

Semen-derived enhancer of viral infection(SEVI) is a peptide fragment (PAP248-286) from prostatic acid phosphatase(PAP), which can enhance human immunodeficiency virus infection. The mechanisms of SEVI include: (1) SEVI with several cationic amino acid residues reduced electrostatic repulsion between HIV virus and the target cells; (2) The disorder state of SEVI in the human body fluids was helpful to the interaction between virus and the target cell membranes; (3) SEVI could capture HIV particles directly and speed the velocity of virus on the surface of the target cells and improve adsorption and fusion. Currently, the substances of inhibiting SEVI activity include: EGCG from green tea, small molecule compound of aminoquinoline Surfen, ThT analogs BTA-EG6. Those compounds might block the combination of HIV and SEVI or prevent the formation of amyloid fibers, and then reduce the enhancement of SEVI. The studies on the biological characteristics and mechanisms of SEVI have a big benefit for the prevention and treatment of HIV infection.

Entities:  

Mesh:

Year:  2012        PMID: 22416356

Source DB:  PubMed          Journal:  Bing Du Xue Bao        ISSN: 1000-8721


  3 in total

Review 1.  A Review of the Antiviral Role of Green Tea Catechins.

Authors:  Jun Xu; Zhao Xu; Wenming Zheng
Journal:  Molecules       Date:  2017-08-12       Impact factor: 4.411

Review 2.  Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19.

Authors:  Ying-Qi Wang; Qing-Sheng Li; Xin-Qiang Zheng; Jian-Liang Lu; Yue-Rong Liang
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

3.  Myricetin antagonizes semen-derived enhancer of viral infection (SEVI) formation and influences its infection-enhancing activity.

Authors:  Ruxia Ren; Shuwen Yin; Baolong Lai; Lingzhen Ma; Jiayong Wen; Xuanxuan Zhang; Fangyuan Lai; Shuwen Liu; Lin Li
Journal:  Retrovirology       Date:  2018-07-16       Impact factor: 4.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.